Compare Natera Inc. Common Stock (NTRA) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Wayfair Inc — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Wayfair Inc trades at $104.22 (market cap $14.35B). The key difference: Natera Inc. Common Stock is far larger — about 4× Wayfair Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| NTRA | W | |
|---|---|---|
Market Cap | $57.03B | $14.35B |
Volume | 1,131,157 | 2,196,186 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $119.05 |
52-Week Low | $179.42 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $56.18B | $16.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Wayfair (W) trades at $107.99, up 1.74% today, with bullish technical signals from moving averages and a consensus price target of $114.13. The company shows strong revenue growth with $12.46B in 2025, though negative net income margins persist. Recent developments include the launch of 'Wayfair Delivers' brand platform and upcoming Q3 2026 earnings release on November 4, 2026.
The outlook remains cautiously optimistic with analyst support (54% buy ratings) and technical momentum, but profitability challenges and high debt-to-asset ratio of 95.11% present significant risks. The stock's current position near resistance at $108 suggests potential for breakout if Q3 earnings beat expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
